VivoSeq
Infectious Disease

Lyme Disease

13

Pipeline Programs↗

7

Active Trials↗

9

Companies Involved↗

Lyme disease is an emerging landscape with 13 programs across 9 companies. The most active players are COMPASS Pathways, Tarsus Pharmaceuticals, Inc., Teva. 1 therapy is approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

15/100

Mech. Concentration

20/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

COMPASS Pathways logo

COMPASS Pathways

1 program

Phase 1T

Tarsus Pharmaceuticals, Inc.

2 programs

Phase 2Teva logo

Teva

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2Moderna logo

Moderna

3 programs

Phase 2Pfizer logo

Pfizer

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

73%

Small molecule

8 of 11 classified programs — the dominant modality here.

27%ALL OTHERSRNA therapy327%

Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 80% of 15 pipeline programs.

Analysis

Trial Status

16

clinical trials

Completed9 · 56%
Recruiting5 · 31%
Active, not recruiting2 · 13%

Clinical Trials

Trial Activity

16 trials

A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults
Recruiting·Pfizer logoPfizer·Phase 3·NCT07226882·200 enrolled
Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease
Recruiting·SState University of New York - Upstate Medical University·Phase 1·NCT06611111·44 enrolled
Ceftriaxone for Post-Treatment Lyme Disease
Recruiting·HHackensack Meridian Health·Phase 1/2·NCT06785402·20 enrolled
Evaluation, Treatment, and Follow-up of Patients With Lyme Disease
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00028080·500 enrolled
A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001539·700 enrolled
An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)
Active, not recruiting·Pfizer logoPfizer·Phase 3·NCT05477524·12,547 enrolled
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TP-05 in Healthy Participants at High Risk of Tick Exposure
Active, not recruiting·TTarsus Pharmaceuticals, Inc.·Phase 2·NCT07562087·722 enrolled
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00001101·194 enrolled
Effects of Psilocybin in Post-Treatment Lyme Disease
Completed·JJohns Hopkins University·Phase 1·NCT05305105·20 enrolled
Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children
Completed·Pfizer logoPfizer·Phase 3·NCT05634811·3,549 enrolled
First Clinical Study of the Safety and Blood Levels of a Human Monoclonal Antibody (2217LS) Against Lyme Disease Bacteria in Healthy People
Completed·MMassBiologics·Phase 1·NCT04863287·44 enrolled
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000938·66 enrolled
Study and Treatment of Post Lyme Disease (STOP-LD)
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000937·55 enrolled
Brain Imaging and Retreatment Study of Persistent Lyme Disease
Completed·National Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00037479·65 enrolled
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
Completed·Moderna logoModerna·Phase 1/2·NCT05975099·807 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)